[clinicaltrials_resource:d331bf90df78df9cd860c47eb934f0d1]
Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma [clinicaltrials:NCT00089193]Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma [clinicaltrials:NCT00118313]Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma [clinicaltrials:NCT00977145]clinicaltrials:NCT02126579
responsible party [clinicaltrials_vocabulary:responsible-party]
[clinicaltrials_resource:d331bf90df78df9cd860c47eb934f0d1]
Bio2RDF identifier
d331bf90df78df9cd860c47eb934f0d1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d331bf90df78df9cd860c47eb934f0d1
investigator affiliation [clinicaltrials_vocabulary:investigator-affiliation]
University of Virginia
investigator full name [clinicaltrials_vocabulary:investigator-full-name]
Craig L Slingluff, Jr
investigator title [clinicaltrials_vocabulary:investigator-title]
Professor, Department of Surgery
organization [clinicaltrials_vocabulary:organization]
identifier
clinicaltrials_resource:d331bf90df78df9cd860c47eb934f0d1
type
label
[clinicaltrials_resource:d331bf90df78df9cd860c47eb934f0d1]
@en